Congenital toxoplasmosis, later relapses and treatment.
Koppe
J G
JG
Department of Ophthalmology, University of Amsterdam, AMC University of Amsterdam, The Netherlands. Janna.Koppe@inter.NL.net
Meenken
C
C
D000328:Adult; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011739:Pyrimethamine / Q000627:therapeutic use; D055502:Secondary Prevention; D015572:Spiramycin / Q000627:therapeutic use; D013411:Sulfadiazine / Q000627:therapeutic use; D013997:Time Factors; D014125:Toxoplasmosis, Congenital / Q000175:diagnosis* / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D000981:Antiprotozoal Agents; D013411:Sulfadiazine; D015572:Spiramycin; D011739:Pyrimethamine